Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Combination Drug Shows Efficacy in Tough-to-Treat Blood Cancer

Researchers may have found a solution to treating a bone marrow cancer proven to be resistant to several standard therapies.

Read More »

GSK builds oncology pipeline as drug shown to help myeloma patients

GlaxoSmithKline said an experimental multiple myeloma treatment showed a meaningful response in patients that have run out of three previous treatment options.

Read More »

NuCana’s Pancreatic Cancer Trial Halted Due to Futility

Shares of U.K.-based NuCana were down more than 21 percent after the company announced suspended enrollment of patients in a late-stage pancreatic cancer study.

Read More »

Teva’s CGRP Inhibitor Reduces Monthly Migraine Days

Teva Pharmaceutical Industries Ltd.’s anti-CGRP drug fremanezumab hit the target reducing monthly migraine days in a late-stage study.

Read More »

AstraZeneca Imfinzi combination fails advanced lung cancer study

A combination of AstraZeneca’s lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations

Read More »

AstraZeneca diabetes drug shows heart failure promise

AstraZeneca made strides toward the company’s goal of adding heart failure to the conditions that can be treated by Farxiga, putting the diabetes drug ahead of a rival medicine from Eli Lilly.

Read More »

Regeneron’s Evinacumab Effective in Treating Rare, Inherited High-Cholesterol Disease

Regeneron Pharmaceuticals announced positive results from the company’s pivotal Phase III clinical trial of evinacumab in homozygous familial hypercholesterolemia (HoFH).

Read More »

Lilly’s Taltz Shows Superiority Over J&J’s Tremfya In Psoriasis Study

Eli Lilly announced that the company’s psoriasis drug Taltz overcame Johnson & Johnson’s Tremfya in a head-to-head study.

Read More »

Regeneron’s Ebola drug outperforms rival in study

Regeneron Pharmaceuticals Inc. said the company’s experimental treatment for Ebola proved superior to a rival therapy from Mapp Biopharmaceutical at preventing death.

Read More »

AstraZeneca’s Tagrisso helps lung cancer patients live longer: study

AstraZeneca Plc said a late-stage study showed the company’s top-selling drug Tagrisso had significantly helped patients with a type of lung cancer live longer without the disease worsening.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom